LON:SBTX

SkinBioTherapeutics Share Forecast, Price & News

GBX 66.80
+0.80 (+1.21 %)
(As of 06/18/2021 10:03 AM ET)
Add
Compare
Today's Range
66
68.99
50-Day Range
58.50
75.50
52-Week Range
14
£300
Volume201,887 shs
Average Volume1.40 million shs
Market Capitalization£104.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SBTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.


About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology; and a research programme with the University of Manchester to investigate and develop microbiome formulations. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.

Headlines

SkinBioTherapeutics : Holding(s) in Company
SkinBioTherapeutics : Holding(s) in Company
June 6, 2021 |  markets.businessinsider.com
SkinBioTherapeutics Plc (SBTX.L)
SkinBioTherapeutics Plc (SBTX.L)
May 5, 2021 |  sg.finance.yahoo.com
SkinBioTherapeutics : Exercise of Warrant
SkinBioTherapeutics : Exercise of Warrant
March 21, 2021 |  markets.businessinsider.com
SkinBioTherapeutics : Price Monitoring Extension
SkinBioTherapeutics : Price Monitoring Extension
March 21, 2021 |  markets.businessinsider.com
SkinBioTherapeutics - Exercise of Warrant
SkinBioTherapeutics - Exercise of Warrant
March 15, 2021 |  proactiveinvestors.com
SkinBioTherapeutics shares rise on lower losses
SkinBioTherapeutics shares rise on lower losses
March 15, 2021 |  marketwatch.com
SkinBioTherapeutics - Second Price Monitoring Extn
SkinBioTherapeutics - Second Price Monitoring Extn
February 7, 2021 |  proactiveinvestors.com.au
Seer Shares Soar 197% in Trading Debut
Seer Shares Soar 197% in Trading Debut
December 4, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.44 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











SkinBioTherapeutics (LON:SBTX) Frequently Asked Questions

What stocks does MarketBeat like better than SkinBioTherapeutics?

Wall Street analysts have given SkinBioTherapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SkinBioTherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were SkinBioTherapeutics' earnings last quarter?

SkinBioTherapeutics Plc (LON:SBTX) released its earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share for the quarter.
View SkinBioTherapeutics' earnings history
.

How has SkinBioTherapeutics' stock been impacted by COVID-19?

SkinBioTherapeutics' stock was trading at GBX 8.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SBTX shares have increased by 685.9% and is now trading at GBX 66.80.
View which stocks have been most impacted by COVID-19
.

Who are SkinBioTherapeutics' key executives?

SkinBioTherapeutics' management team includes the following people:
  • Mr. Stuart John Ashman, CEO & Exec. Director (Age 53, Pay $236.73k)
  • Mr. Douglas John Quinn, CFO, Company Sec. & Exec. Director
  • Dr. Catherine O'Neill, Chief Scientific Officer & Member of Scientific Advisory Board

Who are some of SkinBioTherapeutics' key competitors?

What other stocks do shareholders of SkinBioTherapeutics own?

What is SkinBioTherapeutics' stock symbol?

SkinBioTherapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SBTX."

How do I buy shares of SkinBioTherapeutics?

Shares of SBTX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is SkinBioTherapeutics' stock price today?

One share of SBTX stock can currently be purchased for approximately GBX 66.80.

How much money does SkinBioTherapeutics make?

SkinBioTherapeutics has a market capitalization of £104.73 million.

How many employees does SkinBioTherapeutics have?

SkinBioTherapeutics employs 7 workers across the globe.

What is SkinBioTherapeutics' official website?

The official website for SkinBioTherapeutics is www.skinbiotherapeutics.com.

Where are SkinBioTherapeutics' headquarters?

SkinBioTherapeutics is headquartered at 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom.

How can I contact SkinBioTherapeutics?

SkinBioTherapeutics' mailing address is 15 1 Silk House, Park Green, MACCLESFIELD, SK11 7QJ, United Kingdom. The company can be reached via phone at +44-161-4682760.


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.